ArticleNature medicine2015
CD47 blockade as another immune checkpoint therapy for cancer.
Article in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- CD5L promotes efferocytosis and resolution of retinal ischemic injury.Cell death & disease · 2026Article
- Phagocytic clearance of targeted cells with a synthetic ligand.Nature biomedical engineering · 2026Article
- Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models.Molecular therapy. Oncology · 2025Article
- Localized Delivery of the mRNAs Encoding CD47 Inhibitor and Interleukins 12, 15, and 21 Elicits Robust Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47.Cancer communications (London, England) · 2025Article
- Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy.Biomarker research · 2025Review
- Reviving Dormant Immunity: Millimeter Waves Reprogram the Immunosuppressive Microenvironment to Potentiate Immunotherapy without Obvious Side Effects.Cyborg and bionic systems (Washington, D.C.) · 2025Article
- Non-discriminating engineered masking of immuno-evasive ligands on tumour-derived extracellular vesicles enhances tumour vaccination outcomes.Nature nanotechnology · 2025Article
- STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis.Frontiers in immunology · 2025Article
- Deciphering the role of CD47 in cancer immunotherapy.Journal of advanced research · 2024Review
- Genetically engineered nanomodulators elicit potent immunity against cancer stem cells by checkpoint blockade and hypoxia relief.Bioactive materials · 2024Article
- Deletion of myeloid HDAC3 promotes efferocytosis to ameliorate retinal ischemic injury.Journal of neuroinflammation · 2024Article
- Mechanism and role of nuclear laminin B1 in cell senescence and malignant tumors.Cell death discovery · 2024Review
- Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Tyrosine phosphataseFrontiers in immunology · 2024Review
- Immune checkpoint blockade in hematological malignancies: current state and future potential.Frontiers in oncology · 2024Review
- Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications.Theranostics · 2024Review
- Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.Frontiers in immunology · 2024Review
- Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma.Oncology research · 2024Article
- Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.Blood transfusion = Trasfusione del sangue · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26444633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.